Advances in Universal CAR-T Cell Therapy.

Abstract

Chimeric antigen receptor T (CAR-T) cell therapy achieved extraordinary achievements results in antitumor treatments, especially against hematological malignancies, where it leads to remarkable, long-term antineoplastic effects with higher target specificity. Nevertheless, some limitations persist in autologous CAR-T cell therapy, such as high costs, long manufacturing periods, and restricted cell sources. The development of a universal CAR-T (UCAR-T) cell therapy is an attractive breakthrough point that may overcome most of these drawbacks. Here, we review the progress and challenges in CAR-T cell therapy, especially focusing on comprehensive comparison in UCAR-T cell therapy to original CAR-T cell therapy. Furthermore, we summarize the developments and concerns about the safety and efficiency of UCAR-T cell therapy. Finally, we address other immune cells, which might be promising candidates as a complement for UCAR-T cells. Through a detailed overview, we describe the current landscape and explore the prospect of UCAR-T cell therapy.

• Authors: Haolong Lin, Jiali Cheng, Wei Mu, Jianfeng Zhou, Li Zhu
• Journal: Frontiers in immunology (Front Immunol) Vol. 12 Pg. 744823 ( 2021) ISSN: 1664-3224 [Electronic] Switzerland
• PMID: 34691052 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2021 Lin, Cheng, Mu, Zhou and Zhu.

Chemical References

• Receptors, Chimeric Antigen

Topics

• Humans
• Immunotherapy, Adoptive (methods, trends)
• Receptors, Chimeric Antigen (therapeutic use)